Last update June 10, 2018


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

A methylxanthine with peripheral vasodilatory properties, reduction of blood viscosity and platelet antiaggregant, improving blood flow. It also inhibits the production of TNFα cytokine.
Indicated in chronic peripheral vascular obstruction of limbs. It has been used experimentally in maternal peripartum cardiomyopathy (Garg 2015), in sepsis, including neonatal (Tarnow 2010) and in necrotizing enterocolitis (Patole 2007).
Administered orally 3 times a day

It is excreted in breast milk in clinically negligible amounts (Witter 1985).

Possible side effects are not frequent.

When breastmilk freezes at -15º, pentoxifylline remains stable for 3 weeks (Bauza 1984).

There are very few bibliographical references. It is classified as having low therapeutic efficacy (Canary Islands Health Service 2011, INSALUD 2001).


We do not have alternatives for Pentoxifylline since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Pentoxifylline is also known as

Pentoxifylline in other languages or writings:


Pentoxifylline belongs to this group or family:


Main tradenames from several countries containing Pentoxifylline in its composition:


Variable Value Unit
Oral Bioavail. 55 %
Molecular weight 278 daltons
Protein Binding 70 %
Tmax 1 hours
0.4 -1.6 hours
M/P ratio 0.87 -
Theoretical Dose 0.06 - 0.15 mg/Kg/d
Relative Dose 0.3 - 2 %
Ped.Relat.Dose 0.3 - 1 %


  1. Garg J, Palaniswamy C, Lanier GM. Peripartum cardiomyopathy: definition, incidence, etiopathogenesis, diagnosis, and management. Cardiol Rev. 2015 Abstract
  2. DGF. Dirección General de Farmacia. Servicio Canario de la Salud. Listado de fármacos considerados de Utilidad terapéutica Baja (UTB). None 2011 Full text (in our servers)
  3. Tarnow-Mordi W, Isaacs D, Dutta S. Adjunctive immunologic interventions in neonatal sepsis. Clin Perinatol. 2010 Abstract
  4. Patole S. Prevention and treatment of necrotising enterocolitis in preterm neonates. Early Hum Dev. 2007 Abstract
  5. INSALUD. Área de Gestión de Farmacia. Subdirección General de Atención Primaria. Instituto Nacional de la Salud. Utilidad terapéutica de los medicamentos financiados por el Sistema Nacional de Salud. . 2001 Full text (in our servers)
  6. Witter FR, Smith RV. The excretion of pentoxifylline and its metabolites into human breast milk. Am J Obstet Gynecol. 1985 Apr 15;151(8):1094-7. Abstract
  7. Bauza MT, Smith RV, Knutson DE, Witter FR. Gas chromatographic determination of pentoxifylline and its major metabolites in human breast milk. J Chromatogr. 1984 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM